Radiopharmaceuticals developed for Zr-89-Immuno-PET


Altiparmak Gulec B., YURT ONARAN F.

JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY, 2021 (Journal Indexed in SCI) identifier identifier

  • Publication Type: Article / Article
  • Volume:
  • Publication Date: 2021
  • Doi Number: 10.1007/s10967-021-07922-6
  • Title of Journal : JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY
  • Keywords: Immuno-PET, Molecular imaging, Radiopharmaceuticals, Zr-89, Cancer, POSITRON-EMISSION-TOMOGRAPHY, FACTOR RECEPTOR EXPRESSION, RENAL-CELL CARCINOMA, IMMUNO-PET, BREAST-CANCER, TUMOR UPTAKE, PRECLINICAL EVALUATION, ZR-89-BEVACIZUMAB PET, OXIDE NANOPARTICLES, RADIATION-DOSIMETRY

Abstract

The development of molecular imaging agents used for imaging of cancer tissue is of great importance for the early detection of cancer. Positron emission tomography (PET) radiopharmaceuticals consists of a positron-emitting radionuclide and a molecularstructure. Zr-89-labeled monoclonal antibodies (mAbs), peptides, nanoparticles, proteins, and other compounds are called Zr-89-Immuno-PET and are used in cancer tissue imaging. This review provides a general overview of the potential of molecules labeled with Zr-89 radionuclide, which is chosen due to its long half-life, in preclinical and clinical studies. In light of these studies, radiopharmaceuticals created using nanoparticles have greater potential than those using antibodies.